Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

New Plasmids Developed for Real-Time Monitoring of Key Intracellular Molecules

By BiotechDaily International staff writers
Posted on 28 Mar 2013
New plasmids are now available for real-time assays enabling cell biology as well as drug discovery researchers to visualize and study the in vivo action of target molecules involved in key regulatory cell processes.

ChromoTek GmbH (Munich, Germany) offers the new nanobody based “Chromobody Plasmids” to visualize and measure the action of candidate drugs or other substances of interest on important regulatory processes in living cells. Presently, four plasmids are available: for analyzing the cell cycle, apoptosis, DNA methylation, and cytoskeleton dynamics. A major advantage of the new Chromobody plasmids compared to Chromobody cell lines already available is that researchers can now monitor cellular pathways in their own cells or cell lines simply by carrying out a transfection. Unlike conventional, end-point assays, the Chromobody plasmids allow the fate of endogeneous target proteins to be followed over time, also visually in a movie-like format. Additionally, as the fluorescently labeled intracellular antibodies expressed from these plasmids do not interfere with the activity of their targets, they are extremely useful for high-content screening.

The new product format is equally suitable for academic researchers who want to decipher cellular pathways and for biotech and pharma researchers seeking to enhance their drug discovery and high-throughput screening capabilities. “We are glad to be able to offer our customers a new product format that gives them greater flexibility both in basic cell biology research and in drug discovery and validation processes,” stated Marion Jung, Managing Director of ChromoTek. Researchers who would like to try the Chromobody technology for their own applications can now choose between three options: license a cell line; order assay-ready frozen instant cells via ChromoTek or via CCS (Cell Culture Service, now part of Evotec AG); or purchase a Chromobody plasmid.

Related Links:

ChromoTek



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: The new peptide offers a triple hormone effect in a single-cell molecule (Photo courtesy of Indiana University).

Tripeptide Drug Effectively Controls Metabolic Syndrome in Rodent Model

Promising results in reducing obesity and normalizing glucose metabolism obtained with a synthetic dipeptide drug have been enhanced by the addition of a molecule of a third hormone, glucagon.... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.